





Guideline for prevention of RhD alloimmunization in RhD negative women

Lubusky M.^{1,2}, Prochazka M.¹, Simetka O.³, Holuskova I.⁴

- ¹Department of Obstetrics and Gynecology, University Hospital, Olomouc, Czech Republic
- ²Department of Medical Genetics and Fetal Medicine, University Hospital, Olomouc, Czech Republic
- ³Department of Obstetrics and Gynecology, University Hospital, Ostrava, Czech Republic
- ⁴Department of Transfusion Medicine, University Hospital, Olomouc, Czech Republic

Events following which anti-D immunoglobulin should be given to all RhD negative women with no anti-D antibodies

First trimester indications

termination of pregnancy

spontaneous abortion followed by instrumentation

ectopic pregnancy

chorionic villus sampling

partial molar pregnancy

Second and third trimester indications

100 սօ

amniocentesis

cordocentesis

other invasive prenatal diagnostic or therapeutic procedures

spontaneous or induced abortion

intrauterine fetal death

attempt at external cephalic version of a breech presentation

abdominal trauma

obstetric haemorrhage

Antenatal prophylaxis at 28th weeks of gestation

250 μg

Delivery of an RhD positive infant *

100 μ**g**

Minimal dose: before 20 weeks gestation 5

50 μg (250 IU)

after 20 weeks gestation

100 μg (500 IU)

Timing: as soon as possible, but no later than 72 hours after the event.

In cases where prevention of RhD alloimmunization is not performed within 72 hours of a potentially sensitising event, it is still reasonable to administer anti-D immunoglobulin (IgG anti-D) within 13 days, and in special cases, administration is still recommended up to a maximum interval of 28 days postpartum.

FMH (fetomaternal haemorrhage)

If the amount of fetal erythrocytes which entered the maternal circulation is quantitatively determined, administration of 10 μg IgG anti-D per 0.5 ml of fetal erythrocytes or 1 ml of whole blood is indicated.

- * also if the RhD type of the infant has not been determined or is in doubt
- ** in conjunction with a test to assess the volume of any fetomaternal hemorrhage

Supported by the grant from the Ministry of Health of the Czech Republic IGA NS 10311-3/2009